- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03897465
Comparative Evaluation of the propertieS of the Contact LAyer Dressing LOMatuell Pro® Versus UrgoTul® in the Management of Acute Wounds (SLALOM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Limonest, France
- CICA+
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute wound: traumatic wound (dermabrasion, skin tears, other), small burns 1st and 2nd degree requiring the use of dressings
- Acute wound size between 3 cm² and 24 cm² (wound could be covered by 2 investigational products maximum)
- Wound whose duration is ≤ 3 days
- Both gender with an age ≥ 18 years
- Written confirmation from the study nurse that the patient was informed, orally agreed to participate and to comply with study treatment and planned visits
- Subject able to follow the protocol
Exclusion Criteria:
- Chronic and acute surgical wound
- Infected, moderately to strongly exudative and haemorrhagic wound
- Diagnosed underlying disease (e.g. diabetic neuropathy, stroke, etc.) which as judged by the investigator could interfere with the pain assessment
- Known allergy/hypersensitivity to any of the components of the investigational products
- Participation in other clinical investigation within one month prior to start of investigation
- Pregnant or breast-feeding women
- Person protected by a legal regime (tutorship or guardianship)
- Patients unable to manifest an oral consent to participate (e.g. dementia) or to understand the use of the VAS tool
- Patient not covered by health insurance/social security
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lomatuell Pro
Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
|
Patients will receive Lomatuell Pro dressings during 3 weeks.
Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
|
Active Comparator: UrgoTul
UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
|
Patients will receive UrgoTul dressings during 3 weeks.
UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of wound dressing changes associated with a pain <30 mm on Visual Analog Scale (VAS)
Time Frame: At Visit 2 (Day 3 ± 2 days)
|
A specific ruler will be provided to the investigator in order to measure the VAS score.
The subject will mark on the ruler the point that he/she feels represent his/her perception of his/her current pain.
The VAS score will be directly measured by the investigator with a scale in millimetres.
The VAS score will be filled in the CRF.
|
At Visit 2 (Day 3 ± 2 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete healing: Percentage of epithelialization of the wound at V3 calculated based on a blind assessment from photographs using W.H.A.T. assessment
Time Frame: At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
|
Condition of the wound
Time Frame: At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
The wound bed condition will be evaluated regarding 6 condition items: bleeding, maceration, inflammation, infection, ratio necrotic/ fibrinous/ granulation/ epithelisation tissue, and tissue in-growth in the dressing holes, by means of the following 4-points scale: none, mild, moderate, severe.
The percentage of each modality for each condition items will be calculated.
|
At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Condition of the surrounding skin
Time Frame: At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
The condition of the surrounding skin will be assessed regarding different conditions: inflammatory signs, irritation, allergic rash/eczema, blistering, skin stripping, maceration, dry, trauma to wound edges, product degradation on the skin, hematoma, other.
These condition items will be assessed by means of the scale Yes/No.
The percentage of each modality will be calculated.
|
At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Global assessment of exudate management
Time Frame: At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
This will use a Cochran-Mantel-Haenszel test including treatment groups and baseline wound exudation status (none, light and moderate/heavy).
|
At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Investigator's global assessment of the product
Time Frame: At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
The global assessment of the dressing will be performed by the investigator regarding the following items: ease of handling, ability to maintain its integrity, ease of application, ability to be repositioned during application, conformability, wound adhesion, ability of dressings to stay in place, transparency, ability to transfer wound fluid to the secondary dressing, ease / speed of removal, overall impression, and absence of residue. Each item will be evaluated by means of the following scale: very good, good, poor, and very poor. The percentage of each modality will be presented. |
At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Patient's global assessment of the product
Time Frame: At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
The global assessment of the dressing will be performed by the subject regarding the following items: ability to maintain its integrity, ability of dressings to stay in place, transparency, comfort of the patient, ability to transfer wound fluid to the secondary dressing, ease/speed of removal, overall impression. Each item will be evaluated by means of the following scale: very good, good, moderate, poor, very poor. The percentage of each modality will be presented. |
At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Safety endpoint: frequency and character of device deficiencies (DDs), adverse events (AEs), serious adverse events (SAEs), adverse device effects (ADEs), serious adverse device effects (SADEs)
Time Frame: At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Safety analyses will be descriptive overall and by dressing group.
Any local and general adverse events occurring and those already present, but worsening, during the course of the investigation will be described on the safety population.
Frequencies will be provided per dressing group and overall describing the type of event: device deficiency (DD), adverse event (AE), serious AE (SAE), adverse device effect (ADE), serious ADE
|
At Visit 2 (Day 3 ± 2 days) and Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Daria TROFIMENKO, Lohmann & Rauscher
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-A02288-47
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Wounds
-
Smith & Nephew, Inc.Not yet recruitingChronic Wounds | Acute WoundsCanada
-
SerenaGroup, Inc.MDM Wound Ventures, LLCCompletedChronic Wounds | Acute WoundsUnited States
-
SerenaGroup, Inc.Anacapa Technologies IncCompleted
-
SoftOx Solutions ASUnknown
-
Molnlycke Health Care ABWithdrawnAcute WoundsGermany
-
Vomaris InnovationsCompleted
-
Molnlycke Health Care ABCompleted
-
Prince of Wales Hospital, Shatin, Hong KongChinese University of Hong KongCompletedAcute and Chronic WoundsChina
-
RWTH Aachen UniversityWithdrawnChronic Wounds | Decubiti | Acute WoundsGermany
-
Mylan Inc.FoveaCompletedSurgical Acute WoundsFrance
Clinical Trials on Lomatuell Pro
-
The University of Texas Medical Branch, GalvestonCompletedDiet | Protein | Skeletal MuscleUnited States
-
Cairo UniversityUnknown
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)Recruiting
-
United States Army Research Institute of Environmental...Eastern Michigan UniversityCompletedWeight Loss | Other Effects of High AltitudeUnited States
-
North Florida Foundation for Research and EducationPfizer; US Department of Veterans AffairsUnknownRheumatoid ArthritisUnited States
-
Bolton MedicalActive, not recruitingAortic Dissection Type BUnited States
-
University of AarhusAarhus University Hospital; TrygFonden, Denmark; Sygekassernes Helsefond; Regional... and other collaboratorsCompletedChronic Kidney DiseasesDenmark
-
University Health Network, TorontoPatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Applied... and other collaboratorsActive, not recruitingDysphagiaUnited States, Canada
-
National Cancer Institute (NCI)RecruitingProstate CancerUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark